Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration.
Indian J Ophthalmol
;
2007 Nov-Dec; 55(6): 413-5
Article
in English
| IMSEAR
| ID: sea-72096
ABSTRACT
Recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related macular degeneration (ARMD). Several therapies have been introduced that show promise for halting the progression of this disorder. However, data from controlled clinical trials to test the relative efficacy of different management strategies across the subtypes of disease remain limited. New treatment modalities that target the neovascularization process, including leakage from choroidal neovascularization (CNV), are currently being developed. Vascular endothelial growth factor (VEGF) has been implicated as a key mediator in the pathogenesis of ARMD-related CNV. Anti-VEGF strategies show promise as potential therapeutic agents for the treatment of CNV and are currently undergoing active clinical investigation. Such strategies include anti-VEGF antibodies, anti-VEGF aptamer, gene therapy and protein kinase C inhibition. This article reviews the mechanism of action and rationale for anti-VEGF drugs in ARMD.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Treatment Outcome
/
Practice Guidelines as Topic
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
/
Animals
/
Macular Degeneration
Type of study:
Practice guideline
Language:
English
Journal:
Indian J Ophthalmol
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS